Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Larotrectinib | hsa00030 | Pentose phosphate pathway | 9.38E-07 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Larotrectinib | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Larotrectinib | hsa00190 | Oxidative phosphorylation | 1.00E-02 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Larotrectinib | hsa00220 | Arginine biosynthesis | 4.40E-02 | 1 | P15104 | GLUL | More | | Larotrectinib | hsa00670 | One carbon pool by folate | 1.33E-02 | 2 | P04818, Q99707 | TYMS, MTR | More | | Larotrectinib | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Larotrectinib | hsa00830 | Retinol metabolism | 2.20E-02 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Larotrectinib | hsa00983 | Drug metabolism - other enzymes | 3.32E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Larotrectinib | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Larotrectinib | hsa01230 | Biosynthesis of amino acids | 2.26E-03 | 4 | P51854, P60891, P05089, P37837 | TKTL1, PRPS1, ARG1, TALDO1 | More | | Larotrectinib | hsa01523 | Antifolate resistance | 2.09E-03 | 5 | P41440, Q92820, P04818, P01375, P18054 | SLC19A1, GGH, TYMS, TNF, ALOX12 | More | | Larotrectinib | hsa03010 | Ribosome | 7.34E-03 | 6 | P62753, P62829, P62888, P61927, P61513, P36578 | RPS6, RPL23, RPL30, RPL37, RPL37A, RPL4 | More | | Larotrectinib | hsa03020 | RNA polymerase | 2.51E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | Larotrectinib | hsa03320 | PPAR signaling pathway | 4.55E-02 | 2 | O00767, Q02318 | SCD, CYP27A1 | More | | Larotrectinib | hsa03450 | Non-homologous end-joining | 4.48E-03 | 1 | P78527 | PRKDC | More | | Larotrectinib | hsa04012 | ErbB signaling pathway | 1.91E-02 | 3 | P16333, P19174, P01106 | NCK1, PLCG1, MYC | More | | Larotrectinib | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.02E-02 | 3 | P09341, P02775, Q13651 | CXCL1, PPBP, IL10RA | More | | Larotrectinib | hsa04064 | NF-kappa B signaling pathway | 1.40E-03 | 12 | O00463, P14778, P01584, P01375, Q04759, Q13077, Q16548, P06239, Q8WV28, P24522, P09341, Q9NQC7 | TRAF5, IL1R1, IL1B, TNF, PRKCQ, TRAF1, BCL2A1, LCK, BLNK, GADD45A, CXCL1, CYLD | More | | Larotrectinib | hsa04070 | Phosphatidylinositol signaling system | 1.53E-02 | 2 | Q86XP1, Q96DU7 | DGKH, ITPKC | More | | Larotrectinib | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | | Larotrectinib | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Larotrectinib | hsa04110 | Cell cycle | 1.21E-03 | 7 | Q9UBD5, P06493, P78527, Q14683, P30304, P33981, P01106 | ORC3, CDK1, PRKDC, SMC1A, CDC25A, TTK, MYC | More | | Larotrectinib | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Larotrectinib | hsa04217 | Necroptosis | 1.89E-06 | 17 | P01375, P01568, P48023, Q13489, Q9NQC7, P42224, Q14765, P07900, P08238, P15104, P01584, Q6FI13, Q99878, Q93077, Q9H444, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, CYLD, STAT1, STAT4, HSP90AA1, HSP90AB1, GLUL, IL1B, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP4B, CHMP2A, PPID | More | | Larotrectinib | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Larotrectinib | hsa04380 | Osteoclast differentiation | 2.05E-03 | 12 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | | Larotrectinib | hsa04530 | Tight junction | 3.02E-02 | 3 | Q8TEU7, O00501, P24844 | RAPGEF6, CLDN5, MYL9 | More | | Larotrectinib | hsa04612 | Antigen processing and presentation | 3.84E-05 | 9 | P13765, P48382, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Larotrectinib | hsa04613 | Neutrophil extracellular trap formation | 1.86E-02 | 14 | O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P0C0S5, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AFZ, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Larotrectinib | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | Larotrectinib | hsa04621 | NOD-like receptor signaling pathway | 1.41E-04 | 15 | P01584, P07900, Q14643, P10599, Q9H1Y0, P43490, O00463, P29728, Q05823, P01375, P09341, P49913, P59665, P59666, P12838 | IL1B, HSP90AA1, ITPR1, TXN, ATG5, PBEF1, TRAF5, OAS2, RNASEL, TNF, CXCL1, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Larotrectinib | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Larotrectinib | hsa04625 | C-type lectin receptor signaling pathway | 8.11E-03 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Larotrectinib | hsa04640 | Hematopoietic cell lineage | 4.33E-03 | 12 | P13612, P14778, P27930, P15144, P11836, P25063, P07766, P09693, P01732, P13765, P01375, P01584 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, HLA-DOB, TNF, IL1B | More | | Larotrectinib | hsa04650 | Natural killer cell mediated cytotoxicity | 3.19E-07 | 11 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P01375 | TNF | Tumor necrosis factor | P01375 | TNF | Tumor necrosis factor | 1 | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.761 | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P01375 | TNF | Tumor necrosis factor | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.717 | Q04759 | PRKCQ | Protein kinase C theta type | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.855 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.823 | P01375 | TNF | Tumor necrosis factor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.727 | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | P01375 | TNF | Tumor necrosis factor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.769 | Q04759 | PRKCQ | Protein kinase C theta type | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.849 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.82 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P01375 | TNF | Tumor necrosis factor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.754 | Q04759 | PRKCQ | Protein kinase C theta type | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.918 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.91 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P01375 | TNF | Tumor necrosis factor | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.838 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | P01375 | TNF | Tumor necrosis factor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.814 | Q04759 | PRKCQ | Protein kinase C theta type | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.803 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.846 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P01375 | TNF | Tumor necrosis factor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.814 | Q04759 | PRKCQ | Protein kinase C theta type | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.803 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.846 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| Larotrectinib | hsa04657 | IL-17 signaling pathway | 1.65E-04 | 10 | P07900, O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF, IL1B | More | | Larotrectinib | hsa04658 | Th1 and Th2 cell differentiation | 1.40E-05 | 11 | Q04759, P07766, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765, P23458 | PRKCQ, CD3E, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB, JAK1 | More | | Larotrectinib | hsa04659 | Th17 cell differentiation | 6.58E-05 | 13 | Q04759, Q16539, P06239, P13765, P14778, Q9HBE5, Q9UL17, P23771, P01584, P07766, P09693, P20963, P23458 | PRKCQ, MAPK14, LCK, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, IL1B, CD3E, CD3G, CD247, JAK1 | More | | Larotrectinib | hsa04660 | T cell receptor signaling pathway | 3.35E-05 | 12 | P01375, Q04759, O95267, Q08881, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Larotrectinib | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Larotrectinib | hsa04710 | Circadian rhythm | 4.40E-02 | 1 | O15516 | CLOCK | More | | Larotrectinib | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Larotrectinib | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Larotrectinib | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.17E-02 | 8 | P14778, P01584, P51828, P22694, Q16539, Q14643, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, MAPK14, ITPR1, PRKCQ, CALM2 | More | | Larotrectinib | hsa04912 | GnRH signaling pathway | 4.33E-02 | 6 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB | More | | Larotrectinib | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Larotrectinib | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Larotrectinib | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Larotrectinib | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Larotrectinib | hsa04932 | Non-alcoholic fatty liver disease | 2.36E-03 | 6 | P01375, P49841, P48023, P01584, P12074, O15239 | TNF, GSK3B, FASLG, IL1B, COX6A1, NDUFA1 | More | | Larotrectinib | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Larotrectinib | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.40E-02 | 1 | O00141 | SGK | More | | Larotrectinib | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Larotrectinib | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Larotrectinib | hsa05140 | Leishmaniasis | 1.29E-03 | 13 | P13612, O75015, P14598, P23458, P42224, P13765, O60603, P25963, P01375, P01584, P29350, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, JAK1, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, IL1B, PTPN6, MAPK14, NCF4 | More | | Larotrectinib | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Larotrectinib | hsa05144 | Malaria | 1.52E-04 | 6 | P60033, O60603, P01375, P35443, P01584, P26718 | CD81, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Larotrectinib | hsa05146 | Amoebiasis | 8.10E-05 | 12 | P01584, P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P12814, P08311 | IL1B, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Larotrectinib | hsa05150 | Staphylococcus aureus infection | 1.02E-03 | 7 | P21730, P21462, O75015, P59665, P59666, P12838, P49913 | C5AR1, FPR1, FCGR3B, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | | Larotrectinib | hsa05160 | Hepatitis C | 1.52E-03 | 7 | P60033, O00501, P29728, P49841, P01375, P48023, P01106 | CD81, CLDN5, OAS2, GSK3B, TNF, FASLG, MYC | More | | Larotrectinib | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | | Larotrectinib | hsa05169 | Epstein-Barr virus infection | 3.13E-02 | 9 | P13765, Q13547, O00463, P24522, P01375, P29728, P07766, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, GADD45A, TNF, OAS2, CD3E, CD3G, CD247 | More | | Larotrectinib | hsa05171 | Coronavirus disease - COVID-19 | 3.18E-03 | 7 | P01584, P62753, P36578, P62888, P61927, P61513, P62829 | IL1B, RPS6, RPL4, RPL30, RPL37, RPL37A, RPL23 | More | | Larotrectinib | hsa05202 | Transcriptional misregulation in cancer | 9.93E-04 | 16 | P17844, P14780, P27930, Q15744, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | DDX5, MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Larotrectinib | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Larotrectinib | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Larotrectinib | hsa05231 | Choline metabolism in cancer | 2.60E-02 | 3 | Q9Y259, P19174, P49619 | CHKB, PLCG1, DGKG | More | | Larotrectinib | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.49E-03 | 9 | O95267, P07766, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539 | RASGRP1, CD3E, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14 | More | | Larotrectinib | hsa05310 | Asthma | 8.13E-03 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Larotrectinib | hsa05321 | Inflammatory bowel disease | 1.63E-06 | 8 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B, IL21R | More | | Larotrectinib | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Larotrectinib | hsa05332 | Graft-versus-host disease | 1.75E-05 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Larotrectinib | hsa05415 | Diabetic cardiomyopathy | 1.07E-02 | 6 | P17252, P14598, Q15080, Q16718, O14521, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, GAPDH | More | | |